Allogeneic mesenchymal stem cell infusion for the stabilization offocal segmental glomerulosclerosis

Biologicals

Volumn 41, Issue 6, 2013, Pages 439-445

  Belingheri, Mirco ^a   Lazzari, Lorenza ^a   Parazzi, Valentina ^a   Groppali, Elena ^a   Biagi, Ettore ^b   Gaipa, Giuseppe ^b   Giordano, Rosaria ^a   Rastaldi, Maria Pia ^a   Croci, Daniela ^a   Biondi, Andrea ^b   Rebulla, Paolo ^a   Edefonti, Alberto ^a   Ghio, Luciana ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

Focal segmental glomerulosclerosis; Inflammatory factors; Mesenchymal stem cells

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; PREDNISONE; TACROLIMUS;

ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CONTROLLED STUDY; DISEASE CONTROL; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NEPHROTIC SYNDROME; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; SHORT TANDEM REPEAT; TREATMENT OUTCOME;

FOCAL SEGMENTAL GLOMERULOSCLEROSIS; INFLAMMATORY FACTORS; MESENCHYMAL STEM CELLS;

ADOLESCENT; CELL SURVIVAL; CELLS, CULTURED; FLOW CYTOMETRY; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOPHENOTYPING; KIDNEY TRANSPLANTATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84888005328     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2013.09.004     Document Type: Article

References (46)

1. North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Annual report 2007, Available from:. http://www.springerlink.com/content/d1234m1x23214422/.
2. D'Agati V.D., Kaskel F.J., Falk R.J. Focal segmental glomerulosclerosis. NEngl J Med 2011, 365:2398-2411.
3. Gbadegesin R., Lavin P., Foreman J., Winn M. Pathogenesis and therapy of focal segmental glomerulosclerosis: an update. Pediatr Nephrol 2011, 26:1001-1015.
4. Baum M.A. Outcomes after renal transplantation for FSGS in children. Pediatr Transplant 2004, 8:329-333.
5. Kiffel J., Rahimzada Y., Trachtman H. Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients. Adv Chronic Kidney Dis 2011, 18:332-338.
6. Vinai M., Waber P., Seikaly M.G. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr Transplant 2010, 14:314-325.
7. Okamoto M., Koshino K., Sakai K., Nobori S., Matsuyama M., Ushigome H., et al. Acase of recurrent focal segmental glomerulosclerosis (FSGS) involving massive proteinuria (>50g/day) immediately after renal transplantation. Clin Transplant 2011, 25:53-58.
8. (No authors listed) Nephrotic syndrome in children prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978, 13:159-165.
9. Dello Strologo L., Guzzo I., Laurenzi C., Vivarelli M., Parodi A., Barbano G., et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 2009, 88:417-420.
10. Caldas H.C., Hayashi A.P.C., Abbud-Filho M. Repairing the chronic damaged kidney: the role of regenerative medicine. Transplant Proc 2011, 43:3573-3576.
11. Liang J., Zhang H., Hua B., Wuang H., Lu L., Shi S., et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010, 69:1423-1429.
12. Ringden O., Le Blanc K. Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Pract Res Clin Haematol 2011, 24:65-72.
13. Uccelli A., Laroni A., Freedman M.S. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011, 10:649-656.
14. Pistoia V., Raffaghello L. Potential of mesenchymal stem cells for the therapy of autoimmune diseases. Expert Rev Clin Immunol 2010, 6:211-218.
15. D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003, 23:117-134.
16. Savin V.J., Sharma R., Lovell H.B., Welling D.J. Measurement of albumin reflection coefficient with isolated rat glomeruli. JAm Soc Nephrol 1992, 3:1260-1269.
17. Savin V.J., Sharma R., Sharma M., McCarthy E.T., Swan S.K., Ellis E., et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. NEngl J Med 1996, 334:878-883.
18. Gonzalez E., Ettenger R., Rianthavorn P., Tsai E., Malekzadeh M. Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. Pediatr Transplant 2011, 15:495-501.
19. Lucchini G., Introna M., Dander E., Rovelli A., Balduzzi A., Bonanomi S., et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Am J Transplant 2010, 16:1293-1301.
20. Capelli C., Salvade A., Pedrini O., Barbui V., Gotti E., Borleri G., et al. The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. Cytotherapy 2009, 11:403-413.
21. Gaipa G., Tilenni M., Straino S., Burba I., Zaccagnini G., Belotti D., et al. GMP-based CD133(+) cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy. JCell Mol Med 2010, 14:1629-1634.
22. Oran B., Ozturk K., Cimen D., Vatansev H., Bulut S., Arslan D. Realease of NT-pro brain natriuretic peptide in children before and after adenotonsillectomy. Int J Pediatr Otorhinolaryngol 2013, 77:666-669.
23. Beijing Group of National Research Project for SARS Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. Chin Med J 2003, 116:1283-1287.
24. Marksteiner J., Kemmler G., Weiss E.M., Knaus G., Ullrich C., Mechtcheriakov S., et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2011, 32:539-540.
25. Kagami S., Kakinuma T., Saeki H., Tsunemi Y., Fujita H., Nakamura K., et al. Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis. Clin Exp Immunol 2003, 134:309-313.
26. Lemos-González Y., Rodríguez-Berrocal F.J., Cordero O.J., Gómez C., Páez de la Cadena M. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cencer and head and neck carcinoma. Br J Cancer 2007, 96:1569-1578.
27. Moll G., Rasmusson-Duprez I., von Bahr L., Connolly-Andersen A.M., Elgue G., Funke L., et al. Are therapeutic human mesenchymal stromal cells compatible with human blood?. Stem Cells 2012, 30:1565-1574.
28. Cravedi P., Kopp J.B., Remuzzi G. Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant 2013, 13:266-274.
29. Chatzigeorgiou A., Lyberi M., Chatzilymperis G., Nezos A., Kamper E. CD40/CD40L signaling and its implication in health and disease. Biofactors 2009, 35:474-483.
30. Yang Z., Tao T., Raftery M.J., Youssef P., Di Girolamo N., Geczy C.L. Proinflammatory properties of the human S100 protein S100A12. JLeukoc Biol 2001, 69:986-994.
31. Nakayama T., Watanabe Y., Oiso N., Higuchi T., Shigeta A., Mizuguchi N., et al. Eotaxin-3/CC chemokine ligand 26 is a functional ligand for CX3CR1. JImmunol 2010, 185:6472-6479.
32. Cruikshank W.W., Kornfeld H., Center D.M. Interleukin-16. JLeukoc Biol 2000, 67:757-766.
33. Grieb G., Merk M., Bernhagen J., Bucala R. Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect 2010, 23:257-264.
34. van der Veen B.S., de Winther M.P.J., Heeringa P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal 2009, 11:2899-2937.
35. Brueckmann M., Huhle G., Lang S., Haase K.K., Bertsch T., Weiss C., et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005, 112:527-534.
36. Ghosh A.K., Vaughan D.E. PAI-1 in tissue fibrosis. JCell Physiol 2012, 227:493-507.
37. Sun D., Ma Y., Han H., Yin Z., Liu C., Feng J., et al. Thrombospondin-1 short hairpin RNA suppresses tubulointerstitial fibrosis in the kidney of ureteral obstruction by ameliorating peritubular capillary injury. Kidney Blood Press Res 2011, 35:35-47.
38. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7:505-516.
39. Mishra R., Leahy P., Simonson M.S. Gene expression profiling reveals role for EGF-family ligands in mesangial cell proliferation. Am J Physiol Renal Physiol 2002, 283:F1151-F1159.
40. Kim do H., Li H., Yoo K.Y., Lee B.H., Hwang I.K., Won M.H. Effects of fluoxetine on ischemic cells and expressions in BDNF and some antioxidants in the gerbil hippocampal CA1 region induced by transient ischemia. Exp Neurol 2007, 204:748-758.
41. Bruno S., Bussolati B., Grange C., Collino F., di Cantogno L.V., Herrera M.B., et al. Isolation and characterization of resident mesenchymal stem cells in human glomeruli. Stem Cells Dev 2009, 18:867-880.
42. Wei C., El Hindi S., Li J., Fornoni A., Goes N., Sageshima J., et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17:952-960.
43. Meyer-Schwesinger C., Lange C., Bröcker V., Agustian P., Lehmann U., Raabe A., et al. Bone marrow-derived progenitor cells do not contribute to podocyte turnover in the puromycin aminoglycoside and renal ablation models in rats. Am J Pathol 2011, 178:494-499.
44. Li B., Morioka T., Uchiyama M., Oite T. Bone marrow cell infusion ameliorates progressive glomerulosclerosis in an experimental rat model. Kidney Int 2006, 69:323-330.
45. Morigi M., Rota C., Montemurro T., Montelatici E., Lo Cicero V., Imberti B., et al. Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Stem Cells 2010, 28:513-522.
46. Magnasco A., Ravani P., Edefonti A., Murer L., Ghio L., Belingheri M., et al. Rituximab in children with resistant idiopathic nephrotic syndrome. JAm Soc Nephrol 2012, 23:1117-1124.